Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.05 (market cap $29.60B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77. The key difference: State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FLRN | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $30.86 |
52-Week Low | $205.48 | $30.65 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $216.98, down 1.01% with bearish technical signals. The company shows strong revenue growth from $1.0B in 2022 to $3.7B in 2025, turning profitable with $314M net income. However, recent Q2 2026 earnings missed expectations, and multiple law firms are investigating potential securities fraud. Analyst consensus remains bullish with a $370.07 price target despite recent volatility.
The stock faces near-term pressure from legal investigations and earnings volatility, but strong fundamentals and analyst support suggest long-term potential. Key risks include legal outcomes and execution on growth targets, while the 71% upside to consensus target offers opportunity if the company can maintain its revenue trajectory.
FLRN trades at $30.77, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though the RSI suggests potential oversold conditions. The company has maintained consistent dividend payments of $0.11 per share through mid-2026. Current financial ratios including P/E, P/S, and ROE are unavailable in the provided data, limiting fundamental assessment.
The outlook remains cautious due to bearish technical signals and limited fundamental visibility. Investment opportunity exists in the steady dividend yield, but risks include potential interest rate sensitivity as highlighted in recent financial commentary. Investors should seek updated financial statements for comprehensive analysis given the missing valuation metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →
